Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AbbVie has signed a deal with Halozyme Therapeutics to use the latter's drug delivery platform, Enhanze, to develop and market products.
Subscribe to our email newsletter
The Enhanze platform is based on a proprietary recombinant human hyaluronidase enzyme (rHuPH20) that temporarily degrades hyaluronan, a chain of natural sugars in the body, to aid in the dispersion and absorption of other injected therapeutic drugs.
For AbbVie, the Enhanze technology will allow for more rapid delivery of injectable medications via subcutaneous delivery.
As part of the deal, Halozyme will receive an initial payment of $23m, followed by milestone payments totaling $130m for each of up to nine collaboration targets.
Additionally, Halozyme will also receive tiered royalties from AbbVie if products under the collaboration are commercialized.
Halozyme president and CEO Dr Helen Torley said: "We are pleased that AbbVie, a global leader in the development of novel therapeutics, has chosen Halozyme’s Enhanze platform to augment their development pipeline.
"AbbVie joins a growing number of top pharmaceutical and biotech companies partnering with Halozyme to develop new formulations that will benefit patients worldwide."
According to Halozyme, its proprietary drug delivery platform Enhanze may also benefit subcutaneous biologics by reducing the need for multiple injections.